The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1188-1194.e3 , December 2009

Adrenergic β2-receptor genotype predisposes to exacerbations in steroid-treated asthmatic patients taking frequent albuterol or salmeterol

  • Kaninika Basu, MBBS

      Affiliations

    • Royal Alexandra Children's Hospital, Brighton and Sussex Medical School, Brighton, United Kingdom
    • Tayside Institute of Child Health, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • These authors contributed equally to this work.
    • ,
  • Colin N.A. Palmer, PhD

      Affiliations

    • Population Pharmacogenetics Group, Biomedical Research Institute, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • These authors contributed equally to this work.
    • ,
  • Roger Tavendale, PhD

      Affiliations

    • Population Pharmacogenetics Group, Biomedical Research Institute, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • ,
  • Brian J. Lipworth, FRCP, MD

      Affiliations

    • Asthma and Allergy Research Group, Division of Medicine and Therapeutics, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • ,
  • Somnath Mukhopadhyay, FRCPCH, PhD

      Affiliations

    • Royal Alexandra Children's Hospital, Brighton and Sussex Medical School, Brighton, United Kingdom
    • Tayside Institute of Child Health, Ninewells Hospital and Medical School, Dundee, United Kingdom
    • Corresponding Author InformationReprint requests: Somnath Mukhopadhyay, FRCPCH, PhD, Royal Alexandra Children's Hospital, Brighton BN2 5BE, United Kingdom.

Received 24 December 2008 ,Revised 30 June 2009 ,Accepted 24 July 2009.

References 

  1. Deen JL, Vos T, Huttly SR, Tulloch J. Injuries and noncommunicable diseases: emerging health problems of children in developing countries. Bull World Health Org. 1999;77:518–524
  2. Fuhlbrigge AL, Adams RJ, Guilbert TW, Grant E, Lozano P, Janson SL, et al. The burden of asthma in the United States: level and distribution are dependent on interpretation of the national asthma education and prevention program guidelines. Am J Respir Crit Care Med. 2002;166:1044–1049
  3. British Guideline on the Management of Asthma. British Thoracic Society Scottish Intercollegiate Guidelines Network. Thorax. 2008;63:iv1-121
  4. Jindal SK, Gupta D, Aggarwal AN, Agarwal R. Guidelines for management of asthma at primary and secondary levels of health care in India (2005) [A Consensus Statement Developed under the World Health Organization and Government of India Collaborative Programme (2004-2005)]. Indian J Chest Dis Allied Sci. 2005;47:309–343
  5. National Institutes of Health, National Heart, Lung, and Blood Institute. Global strategy for asthma management and prevention. Bethesda: National Institutes of Health; 2002;
  6. Rachelefsky GS, Shapiro GG, Bergman D, Blessing-Moore J. Pediatric asthma: promoting best practice. Guide for Managing Asthma in Children. Rochester (NY): American Academy of Allergy, Asthma & Immunology; 1999;
  7. Palmer CNA, Lipworth BJ, Lee S, Ismail T, Macgregor DF, Mukhopadhyay S. Arginine-16 beta2 adrenoceptor genotype predisposes to exacerbations in young asthmatics taking regular salmeterol. Thorax. 2006;61:940–944
  8. Bateman ED, Hurd SS, Barnes PJ, Bousquet J, Drazen JM, FitzGerald M, et al. Global strategy for asthma management and prevention: GINA executive summary. Eur Respir J. 2008;31:143–178
  9. Hancox RJ, Sears MR, Taylor DR. Polymorphism of the beta2-adrenoceptor and the response to long-term beta2-agonist therapy in asthma. Eur Respir J. 1998;11:589–593
  10. Israel E, Chinchilli V, Ford J, Boushey H, Cherniack R, Craig T, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet. 2004;364:1505–1512
  11. Israel E, Drazen J, Liggett S, Boushey H, Cherniack R, Chinchilli V, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med. 2000;162:75–80
  12. Taylor D, Drazen J, Herbison G, Yandava C, Hancox R, Town G. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax. 2000;55:762–767
  13. Holgate ST. Exacerbations—the asthma paradox. Am J Respir Crit Care Med. 2005;172:941–942
  14. Milton B, Whitehead M, Holland P, Hamilton V. The social and economic consequences of childhood asthma across the lifecourse: a systematic review. Child Care Health Dev. 2004;30:711–728
  15. Dawson KP, Jandera E, Penna AC. The prehospital management of children with acute asthma. J Paediatr Child Health. 1992;28:321–322
  16. Flores G, Abreu M, Tomany-Korman S, Meurer J. Keeping children with asthma out of hospitals: parents' and physicians' perspectives on how pediatric asthma hospitalizations can be prevented. Pediatrics. 2005;116:957–965
  17. Palmer C, Ismail T, Lee S, Terron- Kwiatkowski A, Zhao Y, Liao H, et al. Filaggrin null mutations are associated with increased asthma severity in children and young adults. J Allergy Clin Immunol. 2007;120:64–68
  18. Palmer CNA, Doney AS, Ismail T, Lee SP, Murrie I, Macgregor DF, et al. PPARG locus haplotype variation and exacerbations in asthma. Clin Pharmacol Ther. 2007;81:13–18
  19. Tavendale R, Macgregor DF, Mukhopadhyay S, Palmer CN. A polymorphism controlling ORMDL3 expression is associated with asthma that is poorly controlled by current medications. J Allergy Clin Immunol. 2008;121:860–863
  20. Basu K, Palmer CNA, Lipworth BJ, McLean WHI, Terron-Kwiatkowski A, Zhao Y, et al. Filaggrin null mutations are associated with increased asthma exacerbations in children and young adults. Allergy. 2008;63:1211–1217
  21. Palmer CNA, Doney AS, Lee SP, Murrie I, Ismail T, Macgregor DF, et al. Glutathione-S-transferase M1 and P1 genotype, passive smoking and peak expiratory flow in asthma. Pediatrics. 2006;118:710–716
  22. Palmer CNA, Irvine AD, Terron-Kwiatkowski A, Zhao Y, Liao H, Lee SP, et al. Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis. Nat Genet. 2006;38:441–446
  23. Bieche I, Olivi M, Champeme MH, Vidaud D, Lidereau R, Vidaud M. Novel approach to quantitative polymerase chain reaction using real-time detection: application to the detection of gene amplification in breast cancer. Int J Cancer. 1998;78:661–666
  24. Lee DK, Jackson CM, Currie GP, Cockburn WJ, Lipworth BJ. Comparison of combination inhalers vs inhaled corticosteroids alone in moderate persistent asthma. Br J Clin Pharmacol. 2003;56:494–500
  25. Hall IP, Blakey JD, Al Balushi KA, Wheatley A, Sayers I, Pembrey ME, et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet. 2006;368:771–779
  26. Drysdale C, McGraw D, Stack C, Stephens J, Judson R, Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci U S A. 2000;97:10483–10488
  27. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the β2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest. 1997;100:3184–3188
  28. Taylor DA, Jensen MW, Aikman SL, Harris JG, Barnes PJ, O'Connor BJ. Comparison of salmeterol and albuterol-induced bronchoprotection against adenosine monophosphate and histamine in mild asthma. Am J Respir Crit Care Med. 1997;156:1731–1737
  29. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ. Effects of montelukast on surrogate inflammatory markers in corticosteroid-treated patients with asthma. Am J Respir Crit Care Med. 2003;167:1232–1238
  30. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to long-acting β2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet. 2007;370:2118–2125
  31. Mitra AD, Ogston S, Crighton A, Mukhopadhyay S. Lung function and asthma symptoms in children: relationships and response to treatment. Acta Paediatr. 2002;91:789–792
  32. Korppi M, Remes K. Asthma treatment in schoolchildren: lung function in different therapeutic groups. Acta Paediatr. 1996;85:190–194
  33. Piippo-Savolainen E, Remes S, Kannisto S, Korhonen K, Korppi M. Early predictors for adult asthma and lung function abnormalities in infants hospitalized for bronchiolitis: a prospective 18- to 20-year follow-up. Allergy Asthma Proc. 2006;27:341–349
  34. Wechsler M, Lehman E, Lazarus S, Lemanske R, Boushey H, Deykin A, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med. 2006;173:519–526
  35. Piippo-Savolainen E, Korppi M. Wheezy babies—wheezy adults? Review on long-term outcome until adulthood after early childhood wheezing. Acta Paediatr. 2008;97:5–11
  36. Korppi M, Kuikka L, Reijonen T, Remes K, Juntunen-Backman K, Launiala K. Bronchial asthma and hyperreactivity after early childhood bronchiolitis or pneumonia. An 8-year follow-up study. Arch Pediatr Adolesc Med. 1994;148:1079–1084
  37. Hyvärinen M, Piippo-Savolainen E, Korhonen K, Korppi M. Teenage asthma after severe infantile bronchiolitis or pneumonia. Acta Paediatr. 2005;94:1378–1383
  38. Kotaniemi-Syrjänen A, Reijonen TM, Korhonen K, Korppi M. Wheezing requiring hospitalization in early childhood: predictive factors for asthma in a six-year follow-up. Pediatr Allergy Immunol. 2002;13:418–425
  39. Stein RT, Holberg CJ, Sherrill D, Wright AL, Morgan WJ, Taussig L, et al. Influence of parental smoking on respiratory symptoms during the first decade of life: the Tucson Children's Respiratory Study. Am J Epidemiol. 1999;149:1030–1037
  40. O'Connor BJ, Aikman SL, Barnes PJ. Tolerance to the nonbronchodilator effects of inhaled beta 2-agonists in asthma. N Engl J Med. 1992;327:1204–1208

 Support for the study was approved by the Gannochy Trust (Perth, Scotland), Scottish Enterprises Tayside, and the Perth and Kinross Council. C. N. A. P. is supported by the Scottish Executive Genetic Health Initiative Award.

 Disclosure of potential conflict of interest: B. J. Lipworth has provided consulting advice regarding the fluticasone/formoterol combination for Mundipharma, provided a speakers' bureau talk on budesonide formoterol for AstraZeneca and a speakers' bureau talk on heterogeneity in asthma and airway remodeling for Merck, has received research support from Merck Sharpe & Dohme and Neolab, and has provided legal consultation on formoterol equivalence for TEVA. S. Mukhopadhyay has served as an expert advisor for and received research support from Merck Sharpe & Dohme. The rest of the authors have declared that they have no conflict of interest.

PII: S0091-6749(09)01150-6

doi: 10.1016/j.jaci.2009.07.043

The Journal of Allergy and Clinical Immunology
Volume 124, Issue 6 , Pages 1188-1194.e3 , December 2009

Article Tools